Kawasaki-like syndrome in COVID‑19 - Symptoms, Causes, Treatment & Prevention

```html

Overview

Kawasaki‑like syndrome in COVID‑19, also referred to as Multisystem Inflammatory Syndrome in Children (MIS‑C) or Multisystem Inflammatory Syndrome in Adults (MIS‑A) when it occurs in adults, is a rare but serious hyper‑inflammatory condition that appears several weeks after infection with SARS‑CoV‑2. It shares many clinical features with classic Kawasaki disease (KD) – a vasculitis that primarily affects children – but it can also involve the heart, gastrointestinal (GI) tract, kidneys, and nervous system.

According to the U.S. Centers for Disease Control and Prevention (CDC), as of April 2024, > 4,800 cases of MIS‑C have been reported in the United States, with an estimated incidence of 2 cases per 100,000 SARS‑CoV‑2 infections in children < 21 years old. MIS‑A is less well‑characterized but appears in < 1 % of hospitalized adults who have recovered from COVID‑19, according to a meta‑analysis published in *The Lancet* (2023). The syndrome most often affects previously healthy school‑age children (median age 9 years) and adolescents, but reports now span infants to adults up to 60 years.

Although the overall prevalence is low, the rapid progression to shock, cardiac dysfunction, or coronary artery aneurysms makes early recognition crucial.

Symptoms

Symptoms develop 2–6 weeks after a confirmed or probable COVID‑19 infection. The presentation can be highly variable; at least two of the following categories are usually required for a clinical diagnosis.

Fever

• Persistent high fever ≥ 38.0 °C (100.4 °F) lasting ≥ 24 hours, often > 40 °C (104 °F).

Mucocutaneous manifestations (Kawasaki‑like features)

• Conjunctival injection – red eyes without discharge.
• Oral changes – strawberry tongue, cracked lips, erythema of oral mucosa.
• Skin rash – polymorphous, often maculopapular, may become desquamating on palms/soles.
• Extremity changes – swelling or redness of hands/feet, later desquamation.

Gastrointestinal symptoms

• Abdominal pain, often severe, sometimes mimicking appendicitis.
• Vomiting and diarrhea (present in ~ 60 % of cases).

Cardiovascular signs

• Chest pain or discomfort.
• Palpitations, tachycardia.
• Hypotension or shock (requiring fluid resuscitation or vasopressors).
• Signs of myocardial dysfunction – reduced ejection fraction on echo.

Respiratory findings

• Shortness of breath, cough – less common than in acute COVID‑19 but may coexist.

Neurologic & other systemic signs

• Headache, lethargy, confusion.
• Muscle aches (myalgia), joint pain.
• Rash on the trunk, conjunctivitis, lymphadenopathy (≥ 1.5 cm cervical node).

Laboratory clues

• Elevated inflammatory markers: C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, D‑dimer.
• Neutrophilia, lymphopenia.
• Elevated cardiac enzymes (troponin, BNP/NT‑proBNP).

Causes and Risk Factors

The exact trigger is unknown, but current evidence points to a dysregulated immune response to SARS‑CoV‑2:

• Post‑infectious hyper‑inflammation: The virus may act as a super‑antigen, activating large numbers of T‑cells and cytokines (IL‑6, IL‑1β, TNF‑α).
• Genetic susceptibility: Certain HLA types (e.g., HLA‑B*58:01) and polymorphisms in immune‑regulatory genes have been linked to higher risk, similar to classic Kawasaki disease.
• Age: Children between 5‑15 years appear most vulnerable; infants < 1 year may have atypical presentations.
• Ethnicity: Higher incidence reported in Black, Hispanic, and South Asian populations in the U.S. and UK, suggesting socioeconomic and genetic contributors.
• Underlying conditions: While most patients are previously healthy, obesity, asthma, and prior cardiac disease may increase severity.

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging findings. The CDC and WHO criteria are similar and include:

Step‑by‑step approach

1. Confirm prior SARS‑CoV‑2 exposure: Positive PCR, antigen test, or serology (IgG) within the previous 2‑12 weeks.
2. Persistent fever ≥ 38 °C for ≥ 24 h.
3. Evidence of multisystem involvement (≥ 2 organ systems) – cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological.
4. Elevated inflammatory markers (CRP, ESR, ferritin, procalcitonin, D‑dimer).
5. Exclusion of alternative diagnoses (bacterial sepsis, toxic shock, severe COVID‑19 pneumonia).

Key investigations

• Blood tests: CBC, metabolic panel, CRP, ESR, ferritin, D‑dimer, fibrinogen, troponin, BNP/NT‑proBNP, cytokine panel (if available).
• Echocardiogram: Assess left ventricular function, pericardial effusion, and coronary artery dimensions – aneurysms develop in 10‑20 % of MIS‑C cases.
• Electrocardiogram (ECG): Look for arrhythmias, ST changes.
• Chest radiograph or CT: Evaluate for pneumonia or pleural effusion.
• Abdominal ultrasound/CT: When severe abdominal pain is present to rule out surgical emergencies.
• SARS‑CoV‑2 testing: PCR (if still positive) and serology for IgG/IgM.

Treatment Options

Management requires a multidisciplinary team (pediatrics, cardiology, infectious disease, rheumatology, intensive care). Early treatment reduces the risk of cardiac sequelae.

First‑line therapy

• Intravenous immunoglobulin (IVIG): 2 g/kg as a single infusion. Reduces fever and inflammation in > 80 % of patients.
• Aspirin: High‑dose (30‑50 mg/kg/day) until afebrile for 48 h, then low‑dose (3‑5 mg/kg) for antiplatelet effect, especially if coronary changes are present.

Adjunctive immunomodulators

• Corticosteroids: Methylprednisolone 1‑2 mg/kg/day (or pulse dosing 10‑30 mg/kg) for refractory cases or shock.
• Biologic agents:
  • IL‑6 inhibitor (tocilizumab) – useful when CRP remains markedly elevated.
  • IL‑1 receptor antagonist (anakinra) – preferred in patients with hyper‑ferritinemia or macrophage activation syndrome.

Supportive care

• Fluid resuscitation and vasopressors (norepinephrine, epinephrine) for shock.
• Oxygen supplementation or mechanical ventilation if respiratory failure occurs.
• Antibiotics (broad‑spectrum) until bacterial infection is excluded.
• Anticoagulation (low‑molecular‑weight heparin) when D‑dimer > 1 µg/mL or if coronary aneurysms are present.

Follow‑up and long‑term care

• Repeat echocardiograms at 2 weeks, 6 weeks, and 1 year.
• Low‑dose aspirin for 6‑12 months if coronary abnormalities persist.
• Cardiology referral for persistent ventricular dysfunction.

Living with Kawasaki‑Like Syndrome in COVID‑19

Even after hospital discharge, families need clear guidance to monitor recovery and prevent relapse.

• Medication adherence: Complete the full IVIG course and keep aspirin on schedule.
• Activity restrictions: Avoid strenuous exercise for at least 4–6 weeks if cardiac involvement was documented.
• Temperature checks: Record daily temperatures; report fever > 38 °C lasting > 24 h.
• Symptom diary: Track chest pain, shortness of breath, palpitations, abdominal pain, or new rash.
• Vaccinations: Keep up‑to‑date with routine vaccines and receive the COVID‑19 booster as recommended; discuss timing with your cardiologist if a recent aneurysm was found.
• School & work: Children can usually return after 24 h afebrile and once cardiac clearance is obtained. Inform teachers about the need for occasional rest periods.
• Psychosocial support: Anxiety about heart health is common; counseling or support groups (e.g., KD Foundation) can be helpful.

Prevention

Because MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 exposure and severity.

• Vaccination: mRNA COVID‑19 vaccines (Pfizer‑BioNTech/Moderna) have shown > 90 % effectiveness in preventing severe disease and appear to lower the incidence of MIS‑C by up to 75 % in adolescents (CDC, 2023).
• Masking & ventilation: In indoor or crowded settings, especially during community surges.
• Hand hygiene: Regular handwashing with soap for ≥ 20 seconds.
• Prompt testing and isolation: Early detection of acute COVID‑19 limits viral load and may blunt the inflammatory cascade.
• Management of underlying conditions: Good control of asthma, obesity, and diabetes reduces overall COVID‑19 risk.

Complications

If untreated or delayed, Kawasaki‑like syndrome in COVID‑19 can lead to serious morbidity.

• Coronary artery aneurysms or ectasia: Occur in ~ 15 % of MIS‑C patients; risk of thrombosis or myocardial infarction.
• Cardiogenic shock: Due to myocarditis or severe ventricular dysfunction.
• Arrhythmias: Ventricular tachycardia, atrioventricular block.
• Thromboembolic events: Deep vein thrombosis, pulmonary embolism, especially with markedly elevated D‑dimer.
• Renal injury: Acute kidney injury requiring dialysis in severe cases.
• Gastrointestinal perforation: Rare but reported when severe abdominal inflammation mimics surgical abdomen.
• Neurologic sequelae: Encephalopathy, seizures, or stroke.
• Long‑term cardiac sequelae: Persistent reduced ejection fraction or diastolic dysfunction.

When to Seek Emergency Care

References

• Mayo Clinic. “Kawasaki Disease.” Updated 2023.
• CDC. “Multisystem Inflammatory Syndrome in Children (MIS‑C).” 2024. https://www.cdc.gov/mis-c
• World Health Organization. “Multisystem inflammatory syndrome in children and adolescents temporarily related to COVID‑19.” 2023.
• Feldstein LR, et al. “Multisystem Inflammatory Syndrome in US Children and Adolescents.” *N Engl J Med*. 2020;383:334‑346.
• McCrindle BW, et al. “Diagnosis, Treatment, and Long‑Term Management of Kawasaki Disease.” *Lancet*. 2022;399:1238‑1249.
• Whittaker E, et al. “Clinical Characteristics of MIS‑A.” *Lancet Respir Med*. 2023;11:678‑688.
• Cleveland Clinic. “COVID‑19 and Kawasaki‑like Inflammatory Syndrome.” 2023.

```